STAT+: Pharmalittle: Pfizer resists requests for study supplies of its Covid pill; WTO talks on Covid vaccine patent waivers are bogged down
Good morning, everyone, and how are you today? The skies over the Pharmalot campus are…
Category: Pharma
STAT+: Pharma wins a court battle over an HHS rule that would have penalized them for offering copay coupons
In a notable win for the pharmaceutical industry, a federal court judge tossed a rule…
STAT+: ‘Pharma bro’ Martin Shkreli released from prison
Martin Shkreli, the infamous ‘pharma bro’ who was sentenced to prison for securities fraud, was…
STAT+: Pharmalittle: Moderna chair defends executive hiring process; analysis finds monopoly tactics preserve inhaler revenues
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Drugmakers use monopoly tactics to thwart lower-cost generic competition for inhalers, analysis finds
For more than three decades, drugmakers have used various tactics to win and extend monopolies…
STAT+: High blood pressure pills are costly — but also hard to find — in some lower-income countries
A clutch of serious challenges — high prices, a lack of effective combination pills, and…
National Academies report cites ‘urgent’ need to recruit more diverse participants for clinical trials
The persistent lack of diversity among participants in clinical trials is a critical issue that…
STAT+: Pharmalittle: FDA declines to approve old antidepressant for Covid; U.S.-China trade fight may derail WTO Covid patent waiver
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Two dozen states side with HHS in its raucous dispute with pharma over a drug discount program
Two dozen states have waded into the heated dispute between the U.S. government and a…
STAT+: Greece plans to go to court to seek compensation from Novartis over a bribery scandal
The Greek health ministry plans to seek compensation from Novartis over a long-running bribery scandal…
STAT+: Pharmalittle: FDA OKs new type of diabetes drug from Lilly; Early-stage biotechs are juicy targets for M&A surge
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Aspen may close South Africa Covid vaccine plant due to lack of orders; Roche insists it can overcome latest setback
And so, another working week will soon draw to a close. Not a moment too…
Opinion: A consultant wrote the playbook on drug pricing — then distanced himself from it
When Biogen announced the price for Aduhelm, its controversial Alzheimer’s drug, the explanation the company…
STAT+: National Institutes of Health licenses nearly a dozen Covid-19 technologies to a WHO program
In a notable bid to widen global access to Covid-19 medical products, the National Institutes…
STAT+: Arkansas becomes the latest state to sue drugmakers and PBMs over insulin pricing
The Arkansas attorney general has filed a lawsuit accusing several drugmakers and pharmacy benefit managers…
STAT+: Pharmalittle: Seagen chief executive is arrested for domestic assault; abortion pill producer has ample supplies
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Lawmakers wade into a contentious and long-running battle over orphan drug monopolies
Sparked by an unusual, decade-long fight over a rare disease drug, two U.S. lawmakers have…
STAT+: Pharmalittle: Moderna’s new CFO leaves due to probe by former employer; Roche suffers another setback with a cancer drug
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Roche anti-TIGIT cancer immunotherapy fails second clinical trial
Roche said Wednesday that its experimental cancer immunotherapy directed against a target called TIGIT suffered…
STAT+: Why a controversial patent rights waiver could be a ‘missed opportunity’ to tackle the next pandemic
After 18 months, the fate of a contentious proposal before the World Trade Organization to…
STAT+: Pharmalittle: Pfizer to pay $11.6 billion for Biohaven; pharmacy chains face a novel trial to determine opioid liability
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
.jpg)
STAT+: Pharmalittle: Seagen CEO under investigation after alleged domestic violence; Bausch & Lomb settles for a lesser IPO
Good morning, one and all. Damian Garde here, filling in for Ed Silverman on another…
STAT+: Pharmalittle: FDA restricts access to J&J Covid-19 vaccine; Novartis halts production of two cancer drugs over quality issues
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Novartis suspends production of two cancer therapies over potential quality issues
Due to manufacturing issues, Novartis has voluntarily suspended production of two therapies that use nuclear…
Opinion: Exploitation in the name of biomedical innovation cannot be tolerated
Biogen’s announcement on Tuesday that it is “substantially eliminating” its spending on Aduhelm caps a…
STAT+: Pharmalittle: Abortion pill demand may rise if Roe v Wade is overturned; U.S. lawmakers move toward revamping accelerated approval
Top of the morning to you. Another deliciously shiny day is unfolding over the Pharmalot…
STAT+: J&J sues a behind-the-scenes company for exploiting its patient assistance program
In the latest dust-up over prescription drug pricing, Johnson & Johnson filed a lawsuit accusing…
STAT+: Race is often overlooked in key clinical trial data used to win new drug approvals in Europe
Just two-thirds of the pivotal clinical trials that were used to win prescription drug approvals…
STAT+: FDA warns Miami University contract testing lab over falsified data, poor quality control
A contract testing laboratory run by Miami University was scolded by the U.S. Food and…
STAT+: Pharmalittle: Biogen is perilously poised for the future; WTO advances controversial Covid-vaccine patent waiver
Top of the morning to you. The middle of the week is upon us and,…
STAT+: A compromise on patent waivers for Covid-19 vaccines takes a key step at the WTO
A controversial proposal before the World Trade Organization to waive patent rights for Covid-19 vaccines…
Opinion: Global health should not be determined by pharma investors and shareholders
What could go wrong when pharmaceutical company shareholders and investors shape the public health response…
STAT+: Pharmalittle: Biogen CEO exits amid Aduhelm failures; FDA eschews its own outside expert panels
Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like…
STAT+: Is the FDA taking advice from its expert panels? A new analysis points to inconsistencies in the process
For decades, the U.S. Food and Drug Administration has relied on outside expert panels for…
STAT+: U.N. committee urges wealthy nations to honor human rights conventions, widen access to Covid vaccines
A United Nations committee urged wealthy nations to support a proposal before the World Trade…
STAT+: Pharmalittle: FDA declines to approve two more drugs tested in China; Pfizer Covid pill fails to prevent infection in household members
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: U.S. Trade Rep report sparks concern that a new clash may occur over clinical trial transparency
A recent Biden administration report on “significant” foreign barriers to U.S. exports suggests that a…
Pfizer vaccine chief Kathrin Jansen, who led Covid effort, to retire
Kathrin Jansen, the vaccine researcher who led Pfizer’s collaboration with BioNTech to develop a Covid-19…
STAT+: Pharmalittle: Investors reject proposals for Covid vaccine makers to share know-how; CMS head says Alzheimer’s drug decision is rare
And so, another working week will soon draw to a close. Not a moment too…
STAT+: The revolving door swings again as Lupin hires an FDA official who oversaw problems at a key plant
The revolving door between the U.S. Food and Drug Administration and the pharmaceutical industry turned…
.jpg)
STAT+: California fines an OptumRx pharmacy for jeopardizing patient health. Is that enough?
The California Board of Pharmacy fined OptumRx, one of the largest pharmacy benefit managers in…
STAT+: Pharmalittle: Amgen faces $7B IRS back-tax bill and fine; McKinsey exec apologizes for opioid work during hearing
Rise and shine. Another busy day is on the way. Indeed, the official to-do list…
STAT+: Pharmalittle: J&J sues wholesalers and a pharmacy over fake HIV meds; Rite Aid to pay $123 million to Humana for inflating drug prices
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT+: Usual and customary? Rite Aid ordered to pay Humana $123 million for inflating pharmacy claims
Rite Aid was ordered by an arbitrator to pay nearly $123 million to Humana, one…
STAT+: Pharmalittle: White House announces Covid-pill push; ‘right-to-try’ think tank is back with a new law
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Thanks to Covid-19, pharma’s reputation improved among patient groups. But can it last?
Thanks to its response to the Covid-19 pandemic, the pharmaceutical industry has greatly improved its…
STAT+: Biden is urged to pursue march-in rights for a pricey cancer drug after NIH delays a petition review
Citing arguments by more than two dozen legal experts, Sen. Elizabeth Warren (D-Mass.) is urging…
STAT+: One in four pharma status reports on follow-up trials are late or aren’t filed
Drug companies failed to submit 11% of status reports for clinical trials they were required…
STAT+: Pharma R&D payments to European researchers are like ‘dark money’
Due to inadequate disclosure policies, drug company payments to European researchers and institutions for R&D…
STAT+: Pharmalittle: Are new ADHD treatments really any better? India moves to reduce dependence on China for pharma ingredients
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…